Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,360 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,150 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (645)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02828124 | A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 25 | Bristol-Myers SquibbINDUSTRY | 4 | Jan 30, 2019 | clinicaltrials |
| NCT02220088 | The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial | terminated | Phase 2 / Phase 3 | 79 | Sun Yat-sen UniversityOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT01855724 | Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer | terminated | Phase 2 | 29 | Hellenic Cooperative Oncology GroupOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT03035006 | Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis | terminated | Phase 1 / Phase 2 | 1 | Taiwan Liposome CompanyINDUSTRY | 1 | Nov 6, 2018 | clinicaltrials |
| NCT02254681 | Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC | terminated | Phase 2 | 6 | Allina Health SystemOTHER | 1 | Oct 3, 2018 | clinicaltrials |
| NCT01425996 | A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 3 | Taiwan Liposome CompanyINDUSTRY | 1 | Aug 21, 2018 | clinicaltrials |
| NCT01921751 | High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery | terminated | Phase 2 | 20 | Radiation Therapy Oncology GroupNETWORK | 1 | Jul 13, 2018 | clinicaltrials |
| NCT02345460 | Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study | terminated | Phase 2 | 1 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 13, 2018 | clinicaltrials |
| NCT00832637 | Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers(Gem-ox) | terminated | Phase 2 | 33 | New Mexico Cancer Research AllianceOTHER | 1 | Jun 29, 2018 | clinicaltrials |
| NCT00459108 | Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Apr 19, 2018 | clinicaltrials |
| NCT02374489 | A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma | terminated | Phase 2 | 9 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 5, 2018 | clinicaltrials |
| NCT02638909 | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies | terminated | Phase 2 | 4 | Criterium, Inc.INDUSTRY | 1 | Apr 2, 2018 | clinicaltrials |
| NCT01359007 | FOLFIRINOX in Patients With Inoperable Pancreatic Cancer | terminated | Phase 2 | 5 | University of OklahomaOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT00878215 | Clinical Application of Image-Guided Liver Surgery | terminated | Phase 2 | 40 | Washington University School of MedicineOTHER | 1 | Feb 13, 2018 | clinicaltrials |
| NCT00955721 | A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer | terminated | Phase 1 / Phase 2 | 9 | University of MiamiOTHER | 1 | Jan 3, 2018 | clinicaltrials |
| NCT02549755 | 11C-acetate for Treatment Response After Radiotherapy for HCC | terminated | Phase 2 | 1 | Justin SimsOTHER | 1 | Nov 22, 2017 | clinicaltrials |
| NCT00003530 | Antineoplaston Therapy in Treating Patients With Primary Liver Cancer | terminated | Phase 2 | 3 | Burzynski Research InstituteOTHER | 1 | Nov 21, 2017 | clinicaltrials |
| NCT02958163 | Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)(HepSTAR) | terminated | Phase 2 | 3 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Nov 7, 2017 | clinicaltrials |
| NCT02821533 | Chemoembolization for Hepatocellular Carcinoma | terminated | Phase 2 | 24 | Chinese University of Hong KongOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT00085410 | Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder | terminated | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00787787 | Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer | terminated | Phase 2 | 41 | University of WashingtonOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT02202785 | A Study of MLN0264 in Patients With Pancreatic Cancer | terminated | Phase 2 | 43 | Millennium Pharmaceuticals, Inc.INDUSTRY | 4 | May 15, 2017 | clinicaltrials |
| NCT00948688 | Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas | terminated | Phase 1 / Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT01379521 | Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC(TRACER) | terminated | Phase 2 | 65 | Novartis PharmaceuticalsINDUSTRY | 3 | May 3, 2017 | clinicaltrials |
| NCT01171482 | Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma | terminated | Phase 2 | 5 | Seoul National University HospitalOTHER | 1 | Apr 26, 2017 | clinicaltrials |
| NCT02819869 | The Combination Effect of Statin Plus Metformin on Relapse-free | terminated | Phase 2 | 3 | Taipei Medical University WanFang HospitalOTHER | 1 | Apr 19, 2017 | clinicaltrials |
| NCT03026803 | A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer | terminated | Phase 2 | 4 | City of Hope Medical CenterOTHER | 1 | Apr 13, 2017 | clinicaltrials |
| NCT01229111 | Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Mar 29, 2017 | clinicaltrials |
| NCT00907166 | A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients | terminated | Phase 1 / Phase 2 | 6 | Cornerstone PharmaceuticalsINDUSTRY | 1 | Mar 21, 2017 | clinicaltrials |
| NCT00576056 | Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC | terminated | Phase 2 | 19 | University of PittsburghOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | terminated | Phase 2 | 2 | Emory UniversityOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT00427973 | AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer | terminated | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2016 | clinicaltrials |
| NCT01151761 | Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation | terminated | Phase 2 | 2 | Stanford UniversityOTHER | 1 | Jul 29, 2016 | clinicaltrials |
| NCT01020812 | Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 11 | Stanford UniversityOTHER | 1 | Jul 27, 2016 | clinicaltrials |
| NCT01888965 | Maintenance Dovitinib for Colorectal and Pancreas Cancer | terminated | Phase 2 | 9 | Georgetown UniversityOTHER | 1 | Jul 19, 2016 | clinicaltrials |
| NCT00971126 | Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC) | terminated | Phase 1 / Phase 2 | 3 | National Health Research Institutes, TaiwanOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT01480817 | Sorafenib VS TACE in HCC Patients With Portal Vein Invasion | terminated | Phase 2 | 2 | Seoul National University HospitalOTHER | 1 | Apr 29, 2016 | clinicaltrials |
| NCT01807156 | Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer | terminated | Phase 2 | 7 | Emory UniversityOTHER | 1 | Apr 22, 2016 | clinicaltrials |
| NCT00975039 | Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma | terminated | Phase 2 | 8 | Steba Biotech S.A.OTHER | 1 | Apr 18, 2016 | clinicaltrials |
| NCT02479178 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck(iNSITE2) | terminated | Phase 2 | 73 | BIND TherapeuticsINDUSTRY | 2 | Apr 14, 2016 | clinicaltrials |
| NCT00582400 | A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver | terminated | Phase 2 | 9 | The University of Texas Medical Branch, GalvestonOTHER | 1 | Feb 19, 2016 | clinicaltrials |
| NCT00532441 | Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas | terminated | Phase 2 | 25 | Gabi Chiorean, MDOTHER | 1 | Feb 12, 2016 | clinicaltrials |
| NCT00864513 | Study of Pemetrexed for Second-Line Pancreas Cancer | terminated | Phase 2 | 17 | Georgetown UniversityOTHER | 1 | Dec 8, 2015 | clinicaltrials |
| NCT01239355 | MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy | terminated | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 5, 2015 | clinicaltrials |
| NCT01539018 | Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE | terminated | Phase 2 | 77 | Egyptian Society of Liver CancerOTHER | 1 | Aug 5, 2015 | clinicaltrials |
| NCT01686880 | Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver(TRYPHON) | terminated | Phase 2 | 10 | Jules Bordet InstituteOTHER | 1 | Jul 1, 2015 | clinicaltrials |
| NCT01029418 | AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 30 | National Cancer Centre, SingaporeOTHER | 1 | Apr 16, 2015 | clinicaltrials |
| NCT00081900 | A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care | terminated | Phase 1 / Phase 2 | 38 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Apr 13, 2015 | clinicaltrials |
| NCT01227018 | PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer | terminated | Phase 2 | 15 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jul 23, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Jan 30, 2019source: clinicaltrials